In PN-related metabolic bone disease, which combination is considered a risk factor for patients with inflammatory bowel disease who require long-term PN?

• A. Hypercalciuria only
• B. Hypercalciuria and aluminum toxicity
• C. Hyperphosphatemia and low magnesium
• D. Vitamin D deficiency only

Answer: (B)

In PN-related metabolic bone disease, two factors that dramatically raise risk are excessive urinary calcium loss and exposure to aluminum from PN solutions. Hypercalciuria indicates the body is losing calcium in the urine, which often reflects or drives bone resorption and weakens bone strength, and it also predisposes to nephrocalcinosis. Aluminum toxicity, a historic and still relevant concern with long-term PN, accumulates in bone and kidney and disrupts mineralization, impairs phosphate metabolism, and worsens osteomalacia. When both occur together, the patient faces both pronounced calcium loss from the urine and a toxin that interferes with bone mineral deposition, markedly increasing the danger of PN-associated bone disease in someone with inflammatory bowel disease who requires extended PN. Other factors like vitamin D deficiency or isolated mineral disturbances can contribute to bone problems, but the combination of hypercalciuria with aluminum toxicity represents the most significant PN-related risk in this context.